Overview
- Editors:
-
-
Zahid H. Siddik
-
Kapil Mehta
Will serve as a single source for the current knowledge on genetic and epigenetic alterations that contribute to the development of drug resistance in cancer cells in form of comprehensive reviews by experts in the field
Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (14 chapters)
-
Front Matter
Pages i-xvii
-
- Gergely Szakács, Kenneth Kin Wah, Orsolya Polgár, Robert W. Robey, Susan E. Bates
Pages 1-20
-
- Dominic Fan, Sun-Jin Kim, Robert L. Langley, Isaiah J. Fidler
Pages 21-52
-
- Tomohisa Yokoyama, Yasuko Kondo, Oliver Bögler, Seiji Kondo
Pages 53-71
-
- Stacey J. Baker, E. Premkumar Reddy
Pages 73-93
-
- Kapil Mehta, Jansina Y. Fok
Pages 95-114
-
- P.S. Hodkinson, Tariq Sethi
Pages 115-135
-
- Dunyaporn Trachootham, Wan Zhang, Peng Huang
Pages 137-175
-
- Ajaikumar B. Kunnumakkara, Preetha Anand, Bharat B. Aggarwal
Pages 177-208
-
-
-
- Elisa Barbarotto, George A. Calin
Pages 257-270
-
- Melissa A. Troester, Jason I. Herschkowitz, Katherine A. Hoadley
Pages 271-294
-
- Natalie Charnley, Catharine West, Pat Price
Pages 295-313
-
- Marion M. Chan, Dunne Fong
Pages 315-342
-
Back Matter
Pages 343-363
About this book
It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.
